Conference report: First Phase IIIb imaging study (ULTIMATE) primarily looking at time course of response to secukinumab in biologic-naïve patients with active psoriatic arthritis shows early synovitis reduction
In study, synovitis was assessed with Power Doppler ultrasonography and use of a standardized ultrasound synovitis score (GLOESS) as the primary endpoint showed objectively that secukinumab reduces synovitis at week 12 versus placebo.
Source:
Biospace Inc.